NCT01704287View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

PHASE2CompletedINTERVENTIONAL

Enrollment

540

Participants

Timeline

Start Date

November 20, 2012

Primary Completion Date

November 16, 2015

Study Completion Date

January 31, 2019

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Carboplatin

Carboplatin per institutional standard

DRUG

Paclitaxel

Paclitaxel per institutional standard

DRUG

Dacarbazine

Dacarbazine per institutional standard

DRUG

Temozolomide

Temozolomide per institutional standard

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01704287 - Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | Biotech Hunter | Biotech Hunter